Biogen IDEC sells off Tysabri plant
The fate of Biogen IDEC’s withdrawn multiple sclerosis drug Tysabri looked bleaker today as the company announced the sale of ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.